Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

Molecular Therapy

Volumn 24, Issue 6, 2016, Pages 1078-1089

  Deniger, Drew C ^a   Pasetto, Anna ^a   Tran, Eric ^a   Parkhurst, Maria R ^a   Cohen, Cyrille J ^b   Robbins, Paul F ^a   Cooper, Laurence J N ^c,d   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF TEXAS   (United States)

^d Ziopharm Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; OKT 3; T LYMPHOCYTE RECEPTOR; TRANSPOSASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A2 ANTIGEN; HLA DQ ANTIGEN; HLA-A*02:01 ANTIGEN; HLA-DQBETA ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; SLEEPING BEAUTY TRANSPOSASE, HUMAN; TRANSPOSON;

ARTICLE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA TRANSPOSITION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSPOSON; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; DNA TRANSPOSABLE ELEMENTS; GENETIC ENGINEERING; HLA-A2 ANTIGEN; HLA-DQ BETA-CHAINS; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPOSASES;

EID: 84962693979     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.51     Document Type: Article

References (66)

1. Rosenberg, SA and Restifo, NP (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62-68.
2. Tran, E, Ahmadzadeh, M, Lu, YC, Gros, A, Turcotte, S, Robbins, PF et al. (2015). Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350: 1387-1390.
3. Klebanoff, CA, Rosenberg, SA and Restifo, NP (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22: 26-36.
4. Rosenberg, SA, Yang, JC, Sherry, RM, Kammula, US, Hughes, MS, Phan, GQ et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557.
5. Hinrichs, CS and Rosenberg, SA (2014). Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257: 56-71.
6. Robbins, PF, Lu, YC, El-Gamil, M, Li, YF, Gross, C, Gartner, J et al. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19: 747-752.
7. Lu, YC, Yao, X, Crystal, JS, Li, YF, El-Gamil, M, Gross, C et al. (2014). Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 20: 3401-3410.
8. Lu, YC, Yao, X, Li, YF, El-Gamil, M, Dudley, ME, Yang, JC et al. (2013). Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol 190: 6034-6042.
9. Tran, E, Turcotte, S, Gros, A, Robbins, PF, Lu, YC, Dudley, ME et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344: 641-645.
10. Tran, E and Rosenberg, SA (2014). T-cell therapy against cancer mutations. Oncotarget 5: 4579-4580.
11. Lawrence, MS, Stojanov, P, Polak, P, Kryukov, GV, Cibulskis, K, Sivachenko, A et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
12. Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA Jr. and Kinzler, KW (2013). Cancer genome landscapes. Science 339: 1546-1558.
13. Crompton, JG, Sukumar, M, Roychoudhuri, R, Clever, D, Gros, A, Eil, RL et al. (2015). Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 75: 296-305.
14. Baitsch, L, Baumgaertner, P, Devêvre, E, Raghav, SK, Legat, A, Barba, L et al. (2011). Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J Clin Invest 121: 2350-2360.
15. Gros, A, Robbins, PF, Yao, X, Li, YF, Turcotte, S, Tran, E et al. (2014). PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246-2259.
16. Maiti, SN, Huls, H, Singh, H, Dawson, M, Figliola, M, Olivares, S et al. (2013). Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36: 112-123.
17. Deniger, DC, Switzer, K, Mi, T, Maiti, S, Hurton, L, Singh, H et al. (2013). Bispecific T-cells expressing polyclonal repertoire of endogenous T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21: 638-647.
18. Ivics, Z, Hackett, PB, Plasterk, RH and Izsvák, Z (1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510.
19. Hackett, PB, Largaespada, DA and Cooper, LJ (2010). A transposon and transposase system for human application. Mol Ther 18: 674-683.
20. Jena, B, Dotti, G and Cooper, LJ (2010). Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044.
21. Kebriaei, P, Huls, H, Jena, B, Munsell, M, Jackson, R, Lee, DA et al. (2012). Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23: 444-450.
22. Singh, H, Huls, H, Kebriaei, P and Cooper, LJ (2014). A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257: 181-190.
23. Peng, PD, Cohen, CJ, Yang, S, Hsu, C, Jones, S, Zhao, Y et al. (2009). Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 16: 1042-1049.
24. Field, AC, Vink, C, Gabriel, R, Al-Subki, R, Schmidt, M, Goulden, N et al. (2013). Comparison of lentiviral and sleeping beauty mediated T cell receptor gene transfer. PLoS One 8: e68201.
25. Cohen, CJ, Gartner, JJ, Horovitz-Fried, M, Shamalov, K, Trebska-McGowan, K, Bliskovsky, VV et al. (2015). Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125: 3981-3991.
26. Haga-Friedman, A, Horovitz-Fried, M and Cohen, CJ (2012). Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. J Immunol 188: 5538-5546.
27. Szymczak, AL, Workman, CJ, Wang, Y, Vignali, KM, Dilioglou, S, Vanin, EF et al. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
28. Singh, H, Figliola, MJ, Dawson, MJ, Olivares, S, Zhang, L, Yang, G et al. (2013). Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8: e64138.
29. Deniger, DC, Yu, J, Huls, MH, Figliola, MJ, Mi, T, Maiti, SN et al. (2015). Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinaselike orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS One 10: e0128151.
30. Geurts, AM, Yang, Y, Clark, KJ, Liu, G, Cui, Z, Dupuy, AJ et al. (2003). Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 8: 108-117.
31. Singh, H, Figliola, MJ, Dawson, MJ, Huls, H, Olivares, S, Switzer, K et al. (2011). Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71: 3516-3527.
32. Gattinoni, L, Lugli, E, Ji, Y, Pos, Z, Paulos, CM, Quigley, MF et al. (2011). A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
33. Alves, NL, van Leeuwen, EM, Remmerswaal, EB, Vrisekoop, N, Tesselaar, K, Roosnek, E et al. (2007). A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha. J Immunol 179: 221-228.
34. Nkwanyana, NN, Gumbi, PP, Roberts, L, Denny, L, Hanekom, W, Soares, A et al. (2009). Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 128(1 Suppl): e746-e757.
35. Hamann, D, Kostense, S, Wolthers, KC, Otto, SA, Baars, PA, Miedema, F et al. (1999). Evidence that human CD8+CD45RA+CD27-cells are induced by antigen and evolve through extensive rounds of division. Int Immunol 11: 1027-1033.
36. Luft, T, Rizkalla, M, Tai, TY, Chen, Q, MacFarlan, RI, Davis, ID et al. (2001). Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation. J Immunol 167: 2529-2537.
37. Chinnasamy, N, Wargo, JA, Yu, Z, Rao, M, Frankel, TL, Riley, JP et al. (2011). A TCR targeting the HLA-A∗0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 186: 685-696.
38. Draper, LM, Kwong, ML, Gros, A, Stevanovi, S, Tran, E, Kerkar, S et al. (2015). Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res 21: 4431-4439.
39. Lanitis, E, Smith, JB, Dangaj, D, Flingai, S, Poussin, M, Xu, S et al. (2014). A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther 25: 730-739.
40. Leisegang, M, Engels, B, Schreiber, K, Yew, PY, Kiyotani, K, Idel, C et al. (2015). Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancer-specific point mutation. Clin Cancer Res (epub ahead of print).
41. Rosati, SF, Parkhurst, MR, Hong, Y, Zheng, Z, Feldman, SA, Rao, M et al. (2014). A novel murine T-cell receptor targeting NY-ESO-1. J Immunother 37: 135-146.
42. Wolint, P, Betts, MR, Koup, RA and Oxenius, A (2004). Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med 199: 925-936.
43. Weidmann, E, Brieger, J, Jahn, B, Hoelzer, D, Bergmann, L and Mitrou, PS (1995). Lactate dehydrogenase-release assay: A reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70: 153-158.
44. Hackett, PB, Ekker, SC, Largaespada, DA and McIvor, RS (2005). Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 54: 189-232.
45. Walisko, O, Schorn, A, Rolfs, F, Devaraj, A, Miskey, C, Izsvák, Z et al. (2008). Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther 16: 359-369.
46. Orchard, PJ, Blazar, BR, Burger, S, Levine, B, Basso, L, Nelson, DM et al. (2002). Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther 13: 979-988.
47. Graef, P, Buchholz, VR, Stemberger, C, Flossdorf, M, Henkel, L, Schiemann, M et al. (2014). Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 41: 116-126.
48. Gattinoni, L, Klebanoff, CA, Palmer, DC, Wrzesinski, C, Kerstann, K, Yu, Z et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626.
49. Casati, A, Varghaei-Nahvi, A, Feldman, SA, Assenmacher, M, Rosenberg, SA, Dudley, ME et al. (2013). Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother 62: 1563-1573.
50. Willoughby, JE, Kerr, JP, Rogel, A, Taraban, VY, Buchan, SL, Johnson, PW et al. (2014). Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol 193: 244-251.
51. Borowski, AB, Boesteanu, AC, Mueller, YM, Carafides, C, Topham, DJ, Altman, JD et al. (2007). Memory CD8+ T cells require CD28 costimulation. J Immunol 179: 6494-6503.
52. Suzuki, T, Ogawa, S, Tanabe, K, Tahara, H, Abe, R and Kishimoto, H (2008). Induction of antitumor immune response by homeostatic proliferation and CD28 signaling. J Immunol 180: 4596-4605.
53. Beane, JD, Lee, G, Zheng, Z, Mendel, M, Abate-Daga, D, Bharathan, M et al. (2015). Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma. Mol Ther 23: 1380-1390.
54. Chacon, JA, Pilon-Thomas, S, Sarnaik, AA and Radvanyi, LG (2013). Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2: e25581.
55. Chacon, JA, Sarnaik, AA, Chen, JQ, Creasy, C, Kale, C, Robinson, J et al. (2015). Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumorinfiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res 21: 611-621.
56. Maus, MV, Thomas, AK, Leonard, DG, Allman, D, Addya, K, Schlienger, K et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20: 143-148.
57. Forget, MA, Malu, S, Liu, H, Toth, C, Maiti, S, Kale, C et al. (2014). Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigenpresenting cells for adoptive immunotherapy of melanoma. J Immunother 37: 448-460.
58. Hackett, PB Jr, Aronovich, EL, Hunter, D, Urness, M, Bell, JB, Kass, SJ et al. (2011). Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11: 341-349.
59. Wang, QJ, Yu, Z, Griffith, K, Hanada, K, Restifo, NP and Yang, JC (2016). Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res 4: 204-214.
60. Blankenstein, T, Leisegang, M, Uckert, W and Schreiber, H (2015). Targeting cancerspecific mutations by T cell receptor gene therapy. Curr Opin Immunol 33: 112-119.
61. Rodenko, B, Toebes, M, Hadrup, SR, van Esch, WJ, Molenaar, AM, Schumacher, TN et al. (2006). Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 1: 1120-1132.
62. Chacon, JA, Wu, RC, Sukhumalchandra, P, Molldrem, JJ, Sarnaik, A, Pilon-Thomas, S et al. (2013). Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8: e60031.
63. Howie, B, Sherwood, AM, Berkebile, AD, Berka, J, Emerson, RO, Williamson, DW et al. (2015). High-throughput pairing of T cell receptor and sequences. Sci Transl Med 7: 301ra131.
64. Han, A, Glanville, J, Hansmann, L and Davis, MM (2015). Corrigendum: Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol 33: 210.
65. Goff, SL, Johnson, LA, Black, MA, Xu, H, Zheng, Z, Cohen, CJ et al. (2010). Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother 59: 1551-1560.
66. Pasetto, A, Frelin, L, Aleman, S, Holmström, F, Brass, A, Ahlén, G et al. (2012). TCRredirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol 189: 4510-4519.